Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna has evolved from being considered as just another "Theranos" into becoming one of the most promising drug companies on the planet. A White House meeting in March 2020 produced $483 million from Operation Warp Speed and approved clinical trials for Moderna's COVID vaccine candidate.

Moderna: Curing What Ails A Portfolio

SOUTH SAN FRANCISCO, Calif. and PARIS, April 27, 2021 /PRNewswire/ -- DNA Script today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program.

DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA

Sanofi

As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks.

Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

The shots could be geared towards children, new variants or boosters.

Moderna Receives Vaccine-Making Boost As Sanofi Signs Up To Manufacture 200 Million Doses For Americans

French drug maker Sanofi S.A. has agreed to make Moderna Inc.'s COVID-19 vaccine at its site in Ridgefield, New Jersey, and will fill and finish up to 200 million doses starting in September.

Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Sanofi for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Over the past three months, MRNA insiders have been bailing out of MRNA. MRK and AZN have also sold sizeable equity stakes in MRNA.

Moderna: Insiders Are Bailing Out

Teladoc

Top Stock for 2021: Moderna or Teladoc?

Inovio Pharmaceuticals

There's real value in being a first-mover.

Even as the Stock Market Rose Friday, Investors Got a Harsh Reminder

Moderna Inc. CEO Stephane Bancel said Friday that the company is on track to produce 1 billion doses of its COVID-19 vaccine this year, but warned that with manufacturers producing large quantities, there could be an oversupply in 2022.

Moderna CEO: COVID-19 vaccine surplus possible in 2022

The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 3% during intraday trading today. This is why it happened.

MRNA Stock: Over 3% Increase Intraday Explanation

BioNTech SE

Pfizer

Money and pipelines are the two most important factors in picking the most likely to succeed.

The Biggest mRNA Winner: Pfizer, BioNTech, Moderna, or an Under-the-Radar Biotech?

In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.

Moderna (MRNA) Stock Moves -0.83%: What You Should Know

Almost a decade ago, Flagship Pioneering, a VC fund run and majority-owned by Moderna Inc's (NASDAQ: MRNA) chairman and co-founder, Noubar Afeyan, poured cash into the company, even when Moderna had faced some early setbacks. Over the last 13 months, since the World Health Organization declared a pandemic, Flagship has sold off Moderna shares worth more than $1.4 billion, as reported by Forbes.

Moderna's Flagship Venture Firm Cashed $1.4B From Stock Sale In Two Months: Forbes

Amazon

Amazon.com, Inc. (NASDAQ:AMZN) shares are trading higher by 0.4% after Oppenheimer analyst Jason Helfstein maintains with an Outperform and raises the price target from $4,100 to $4,200. As one of the world's highest-grossing e-commerce platforms, Amazon is more than retail services alone.

So What's Up With Amazon And Moderna Today?

AstraZeneca

Biogen

Johnson & Johnson

Sarepta Therapeutics

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Israel for 2022.

Moderna Announces New Supply Agreement with Israel for 2022

Its COVID-19 vaccine is producing Moderna's first ever product sales, though the company still generates most of its revenue from grants.

How Moderna Makes Money: Grants Generate the Majority of Revenue

Pfizer recently said that people who have received both doses of their Covid-19 vaccine would likely require a booster shot and potentially require an annual shot thereafter, much like seasonal flu shots. Moderna, too, has indicated that it would have a booster shot ready by this fall.

Will A Third Covid-19 Vaccine Dose Boost Moderna Stock?

Moderna can benefit from its rivals' vaccine problems by signing new supply agreements in an already undersupplied market. Moderna's COVID-19 vaccine is one of the industry leaders in efficacy rates, making it one of the best vaccines available on the market.

Moderna: Setbacks For Other Vaccines Will Benefit Moderna

Is It Too Late to Buy Moderna After Its 40% Gain?

Moderna's investor presentation on Wednesday showcased the Massachusetts-based biotech's efforts to develop vaccines against HIV and eight other infectious diseases. The company's mRNA technology, which has built upon decades of research, will now contribute to the long frustrated effort to contain the global HIV/AIDS epidemic.

Moderna's mRNA technology could help in the decades-long search for an HIV vaccine

Novavax

The Moderna CEO's Bold Statement That May Mean Bad News for Novavax

Coronavirus vaccine maker Moderna and vaccine suppliers Maravai and West Pharmaceutical are among five stocks in or near buy zones. The post Coronavirus Vaccine Plays Moderna, Maravai Among 5 Stocks Near Buy Points appeared first on Investor's Business Daily.

Coronavirus Vaccine Plays Moderna, Maravai Among 5 Stocks Near Buy Points

J&J asked Covid vaccine rivals Pfizer and Moderna to join a study looking into the potential risk of blood clots, the Wall Street Journal reported.

News for Moderna Stock (MRNA)